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Abstract
 
Tissue neovascularization involves recruitment of circulating endothelial progenitor cells that
originate in the bone marrow. Here, we show that a class of embryonic endothelial progenitor
cells (Tie-2
 
 
 
, c-Kit
 
 
 
, Sca-1
 
 
 
, and Flk-1
 
 
 
/low), which were isolated at E7.5 of mouse devel-
opment at the onset of vasculogenesis, retain their ability to contribute to tumor angiogenesis
in the adult. Using intravital fluorescence videomicroscopy, we further defined the multistep
process of embryonic endothelial progenitor cell (eEPC) homing and incorporation. Circulating
eEPCs are specifically arrested in “hot spots” within the tumor microvasculature, extravasate into
the interstitium, form multicellular clusters, and incorporate into functional vascular networks.
Expression analysis and in vivo blocking experiments provide evidence that the initial cell arrest
of eEPC homing is mediated by E- and P-selectin and P-selectin glycoprotein ligand 1. This
paper provides the first in vivo insights into the mechanisms of endothelial progenitor cell
recruitment and, thus, indicates novel ways to interfere with pathological neovascularization.
Key words: intravital ﬂuorescence videomicroscopy • neovascularization • cell trafﬁcking • 
PSGL-1 • selectins
 
Introduction
 
Circulating endothelial progenitor cells (EPCs),
 
*
 
 mobilized
from the bone marrow into the blood stream, contribute to
new blood vessel formation and, thus, promote neovascu-
larization during tissue ischemia, vascular trauma, and tumor
growth (1–10). However, the molecular and cellular mech-
anisms underlying EPC recruitment and differentiation are
not yet understood, and remain as one of the central issues
in stem cell biology (11). For instance, it is unclear how
circulating EPCs specifically home to angiogenic sites,
which critical steps underlie their incorporation into new
blood vessels, and how effectively these processes compare
with the activation of local, preexisting endothelial cells (12).
A hindering factor for a systematic analysis of EPC hom-
ing mechanisms is the fact that adult EPCs are difficult to
isolate, maintain, and genetically manipulate in vitro.
Therefore, in this paper, we investigated the mechanisms of
homing and incorporation of EPCs during new blood ves-
sel formation in a tumor model using mouse embryonic
EPCs (eEPCs) as a model system (13). The major advan-
tages of eEPCs are their robust growth properties in culture
and practical genetic manipulation. The eEPCs express
early endothelial markers, differentiate to mature endo-
thelial cells, form vascular tubes in vitro, and build blood
vessels after transplantation during embryogenesis (13).
Their gene expression profile (
 
tie-2
 
, 
 
thrombomodulin
 
,
 
GATA-4
 
, 
 
GATA-6
 
, etc.) matches the pattern observed in
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Abbreviations used in this paper:
 
 DiI, 1,1
 
 
 
-dioctadecyl-3,3,3
 
 
 
,3
 
 
 
-tetra-
methylindocarbocyanine perchlorate; EGFP, enhanced green fluorescent
 
protein; EPC, endothelial progenitor cell; eEPC, embryonic EPC;
PECAM-1, platelet–endothelial cell adhesion molecule-1; PSGL-1,
P-selectin glycoprotein ligand 1; RT, reverse transcriptase; VEGF, vascu-
lar endothelial growth factor.T
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the proximal lateral mesoderm that will give rise to the em-
bryonic endocardium and myocardium. However, the iso-
lated cells do not express, or are not induced to express un-
der a variety of conditions, early myocardial-specific genes
(
 
Nkx2.5
 
 or 
 
MLC2a
 
) and, thus, appear committed to the
endothelial lineage. This notion is further supported by
transplantation studies in embryos that showed differentia-
tion of these cells only toward the endothelial lineage and
no other emerging cell types were observed (13). Extensive
flow cytometry analysis with a large number of antibodies
(e.g., against tie-2, c-kit, VE-cadherin, CD44, etc.), showed
that the in vitro–expanded embryonic cells constitute a ho-
mogeneous population (unpublished data).
Based on these properties, we were able to use eEPCs in
the powerful intravital fluorescence videomicroscopy tech-
nique to visualize the fate of circulating enhanced green
fluorescent protein (EGFP)– or DiI-labeled eEPCs during
tumor angiogenesis. This experimental approach allowed
us first to demonstrate that ex vivo–expanded eEPCs can
contribute to tumor-induced blood vessel growth in the
adult, and, second, to define the multistep interaction of
eEPCs with angiogenic tumor blood vessels. The results
provide a first insight into the mechanisms underlying re-
cruitment, homing, and vascular incorporation of EPCs as
a basis for the design of novel means to therapeutically
manage angiogenic processes.
 
Materials and Methods
 
Isolation and Labeling of eEPCs.
 
The procedures for the isola-
tion and ex vivo expansion of the eEPCs from E7.5 mouse em-
bryos, as well as their differentiation with cAMP and retinoic
acid, have been described previously in detail (13). We fluores-
cently labeled the isolated eEPCs either by the lipid soluble
dye DiI (1,1
 
 
 
-dioctadecyl-3,3,3
 
 
 
,3
 
 
 
-tetramethylindocarbocyanine
perchlorate; Molecular Probes; references 14, 15) or by genetic
labeling using an EGFP (CLONTECH Laboratories, Inc.) con-
struct under the phosphoglycerate kinase promoter. To this end,
1.5–2.0 
 
 
 
 10
 
7
 
 eEPCs were suspended in 20 ml HSB (25 mM
Hepes, pH 7.1, 134 mM NaCl, 5 mM KCl, and 0.7 mM
Na
 
2
 
HP0
 
4
 
), washed once with 10 ml HSB, centrifuged, resus-
pended in 0.8 ml HSB buffer, and transferred to a 0.8-ml elec-
troporation cuvette. We added 30 
 
 
 
g of plasmid DNA and
placed the cells on ice for 10 min. eEPCs were electroporated at
350 V, 500 
 
 
 
F using a Gene Pulser II (Bio-Rad Laboratories)
and were placed on ice for 10 min. The electroporated cells were
transferred to 24 ml of culture medium and plated. The next day,
we started selection with 200–400 
 
 
 
g/ml G418 (Invitrogen) and
proceeded for 10–14 d, exchanging medium daily. Colonies were
picked and expanded for further analysis.
 
RNA Analysis.
 
We prepared RNA using the isolation kit
from QIAGEN and reverse-transcribed total RNA into cDNA as
follows: 1 
 
 
 
g RNA was mixed with 100 ng oligo(dT)
 
15
 
 and in-
cubated for 5 min at 65
 
 
 
C. 1 mM dNTPs, 60 mM KCl, 15 mM
Tris-Cl, pH 8.4, 3 mM MgCl
 
2
 
, 0.3% Tween 20, 10 mM 
 
 
 
-mer-
captoethanol, 10 U RNasin (Promega), and 100 U Mo-MLV
RT (Invitrogen) were added, and the mix was incubated for 55
min at 37
 
 
 
C followed by a second incubation period of 5 min at
95
 
 
 
C. Reverse transcriptase (RT)–PCR was performed with 20 ng
cDNA using Taq DNA polymerase (Promega) for 30–35 cycles
 
(1 min at 95
 
 
 
C, 1 min at 60–65
 
 
 
C, and 1 min at 72
 
 
 
C). The
primer sequences were as follows: flk-1, 5
 
 
 
-ggaATTCAGGCAT-
TGTACTGAGAG-3
 
 
 
, 5
 
 
 
-cggaTCCAAGTTGGTCTTTTC-
CTG-3
 
 
 
; tie-2, 5
 
 
 
-CAACAGCGTCTATCGGACTCC-3
 
 
 
, 5
 
 
 
-
GAAAAGGCTGGGTTGCTTGATC-3
 
 
 
; von Willebrand Fac-
tor (vWF), 5
 
 
 
-ggaattcTGCTCAGTGGGGTGGATG-3
 
 
 
, 5
 
 
 
-cg-
gatccGGGCTCACGTCCATGCGC-3
 
 
 
; c-Kit, 5
 
 
 
-GAGACGT-
GACTCCTGCCATCATG-3
 
 
 
, 5
 
 
 
-CATTTCGGCAGGCGC-
GTGCTC-3
 
 
 
; vascular endothelial growth factor (VEGF)-A, 5
 
 
 
-
GGGTGCACTGGACCCTGGCT-3
 
 
 
, 5
 
 
 
-GAATTCACCGC-
CTCGGCTTGTC-3
 
 
 
; TGF
 
 
 
, 5
 
 
 
-GAGACGGAATACAGGG-
CTTTCG-3
 
 
 
, 5
 
 
 
-CGGGTTGTGTTGGTTGTAGAGG-3
 
 
 
;
GAPDH, 5
 
 
 
-CTCACTCAAGATTGTCAGCAATG-3
 
 
 
, 5
 
 
 
-
GAGGGAGATGCTCAGTGTTGG-3
 
 
 
; aldolase, 5
 
 
 
-AGCTG-
TCTGACATCGCTCACCG-3
 
 
 
, 5
 
 
 
-CACATACTGGCAGC-
GCTTCAAG-3
 
 
 
; sca-1, 5
 
 
 
-GGTTGCAGCAGGCTATGCAA-
GCC-3
 
 
 
, 5
 
 
 
-CGGCTTCCTAGGTGCCAGGCC-3
 
 
 
 (16);
E-selectin ligand, 5
 
 
 
-GCGGCTTCATGGATGACTGC-3
 
 
 
, 5
 
 
 
-
ATGGTGTTCAATCTCCCCTCG-3
 
 
 
; P-selectin ligand, 5
 
 
 
-
CCACCGTGGTCATGCTAGAG-3
 
 
 
, 5
 
 
 
-GACTTCGGTGG-
CTGCAGACG-3
 
 
 
; E-selectin, 5
 
 
 
-GCTGTCCAGTGTGAA-
GCCTTATC-3
 
 
 
, 5
 
 
 
-GCAATGAGGACGATGTCAGGA-3
 
 
 
;
P-selectin, 5
 
 
 
-GCTTCAGGACAATGGACAGC-3
 
 
 
, 5
 
 
 
-CTTT-
CTTAGCAGAGCCAGGAGTG-3
 
 
 
; and ICAM-2, 5
 
 
 
-GGG-
TCTGGTGAGAAGGCCTTTGAGG-3
 
 
 
, 5
 
 
 
-GGGGACACC-
GTGCACTCAATGG-3
 
 
 
. Lowercase letters indicate nucleotides
added for cloning purposes.
 
Tumor Model for Intravital Microscopy.
 
We grew highly angio-
genic rat C6 glioma tumor grafts within the skinfold chamber
preparation of nude mice (NMRI nu/nu; 
 
n 
 
  
 
10), i.e., a transpar-
ent chamber model that allowed direct and noninvasive assessment
of the tumor microcirculation using intravital microscopy (17, 18).
Before tumor inoculation, the C6 cells were incubated with the
fluorescent marker Fast Blue (Sigma-Aldrich) that allowed identi-
fication of the tumor mass by intravital microscopy at an excitation
wavelength of 365 nm (19). After the tumors had established their
microvascular system and initiated tumor growth (
 
 
 
50 mm
 
3
 
) by
day 10–14 after implantation, we inserted a polyethylene catheter
(PE-10) into the right common carotid artery for systemic admin-
istration of fluorescent markers and injection of cells (19).
 
Intravital Fluorescence Videomicroscopy.
 
We performed intravital
multifluorescence videomicroscopy as described previously (14,
19, 20). Depending on the labeling technique for the eEPCs, we
visualized individual microvessels by injection of either FITC- or
rhodamine G–conjugated dextrans. This way, the distinct excita-
tion wavelengths of the marker combinations allowed for local-
ization of the eEPCs with respect to the blood vessel lumina. Af-
ter visualization of the tumor microvasculature, 4 
 
 
 
 10
 
5
 
 either
DiI- or EGFP-labeled eEPCs suspended in 300 
 
 
 
l PBS, were in-
fused in 100-
 
 
 
l aliquots. This protocol allowed us to assess the
dynamic interaction between eEPCs and the tumor endothelium
within three different microvascular regions (size 
 
 
 
 0.8 mm
 
2
 
).
To exclude recirculating cells from the analysis, we limited the
observation period after cell injection to 20 s and waited for an-
other 5 min to the next cell infusion. We repeatedly scanned the
tumor microvasculature at 10 min, 1 h, 1 d, and 4 d after cell in-
jection to assess permanent eEPC–endothelium interactions. At
the end of these experiments, the heart, lung, liver, spleen, and
pancreas were exposed in eight animals for intravital microscopic
assessment of eEPC presence in these tissues. Chamber prepara-
tions without implanted tumors served as controls for the recruit-
ment experiments (n   4). Animals with tumors implanted into
the skinfold chamber but injected with PBS instead of eEPCsT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
1757 Vajkoczy et al.
served as controls to address the consequences of eEPC injection
on tumor vascularization and tumor growth (n   5).
To study the role of P-selectin glycoprotein ligand 1
(PSGL-1) for eEPC recruitment to the tumor endothelium,
we preincubated 4   105 DiI-labeled eEPCs with 215  g
4RA10 (anti–mouse PSGL-1) in 500  l PBS for 20 min (n  
3 animals). Subsequently, we centrifuged the eEPCs and
washed them once with PBS before injection. To study the
role of E-/P-selectin, we injected mice with 300  g UZ4
(anti–mouse E-selectin) and 300  g RB40.34 (anti–mouse
P-selectin) in 200  l PBS 20 min before the infusion of EPCs
(n   3). The monoclonal antibody MJ7/18 served as the con-
trol (n   3) because it binds to the vascular wall without af-
fecting endothelial cell adhesion and was successfully used as a
control previously (20).
Intravital Microscopic Image Analysis. Quantitative analysis in-
cluded the tumor area, total vessel density, diameter of individual
blood vessels, mean blood flow velocity, shear rate, and shear
stress (20, 21, 22). During cell injection, we determined the ab-
solute number of eEPCs that passed through and were arrested
within the microvascular region of interest. Furthermore, we
separated cells that were permanently arrested within the mi-
crovasculature into adherent and plugging categories, depending
on the mechanism of their arrest. We identified adherent eEPCs
as cells that stuck to the vessel wall without moving or detaching
from the endothelium, despite an unaltered microvascular blood
flow. We defined plugging eEPCs as cells that were passively ar-
rested either by blocking the lumen of small blood vessels or by
being trapped within individual vascular sprouts. We quantified
eEPC arrest as the number of adherent and plugging cells per
area (mm 2).
Hemodynamic parameters were quantitatively determined as
described previously (22, 23). In brief, the quantitative analysis
included the diameter of control postcapillary venules and tumor
microvessels as well as the velocity of nonadherent EPCs. The
highest cell velocity per venule, vmax, was used to calculate the
mean blood flow velocity ( m/s): vmean   vmax/(2  2), where  
is the ratio of the EPC diameter to vessel diameter (d). From
vmean and d, the wall shear rate ( [s 1]) was estimated as     8  
vmean /d and the shear stress (  [dyne/cm2]) was approximated by
        0.025. Due to the high spatial resolution of the intravital
microscopic technique, these analyses were performed not only
for the individual tumor in general but also within different intra-
tumoral areas (e.g., “hot spots” for eEPC adherence).
Subcutaneous Tumor Xenografts. To further study the influence
of EPC injection on tumor growth, rat C6 glioma xenografts
were grown subcutaneously after injection of 5   105 C6 cells
into the left flank regions of nude mice (NMRI nu/nu). After the
tumors had been established (by day 8 after implantation), 4  
105 DiI-labeled eEPCs, suspended in 300  l PBS, were infused
into the animals (n   4). Control animals were injected with PBS
alone (n   4). Tumor growth was assessed using vernier calipers
until day 17 after implantation (i.e., as soon as weight loss started
to exceed 20%). Tumor volume was calculated as (length  
width   height)/2.
Detection of eEPCs by Immunofluorescence and Immunohistochemis-
try. We detected the eEPCs by immunofluorescence micros-
copy of serial frozen sections. Vessels containing eEPCs were
counterstained with a monoclonal rat anti–mouse platelet–endo-
thelial cell adhesion molecule-1 (PECAM-1) antibody (BD Bio-
sciences), followed by staining with a goat anti–rat Cy3-conju-
gated IgG (Dianova). We performed immunohistochemistry on
6- m frozen tumor sections as described previously (24).
Monoclonal Antibodies and Ig Chimeras. Mec13.3 (anti–mouse
PECAM-1/CD31) was a gift from Dr. E. Dejana (Federazione
Italiana per la Ricerca sul Cancro-Institute of Molecular Oncol-
ogy, Milan, Italy; reference 25). The hybridomas Hermes-1 ( 
9B5, anti–human CD44, used as an isotype-matched control),
MECA-79 (anti–mouse PNAd), MECA-367 and MECA 89
(both anti–mouse MAdCAM-1), and MJ7/18 (anti–mouse en-
doglin) were obtained from American Type Culture Collection.
RB40.34/4 (anti–mouse P-selectin), 4RA10 (anti–mouse PSGL-
1), 10E9.6 (anti–mouse E-selectin), 25 ZC7 (anti–mouse ICAM-
1), and 9DB3 (anti–mouse VCAM-1) were raised in D. Vestwe-
ber’s laboratory; UZ4 (anti–mouse E-selectin; 26) provided by
Dr. R. Hallmann (The Jubileum Institute, Lund, Sweden). 3C4
(anti–mouse ICAM-2) was purchased from BD Biosciences.
E- and P-selectin IgG chimeras were raised in D. Vestweber’s
laboratory and described previously in detail (27, 28). The tie2
IgG chimera was a gift from Dr. U. Deutsch (Max-Planck Insti-
tute for Vascular Biology, Münster, Germany).
Flow Cytometry. Suspended eEPCs were incubated with 5
 g/ml anti–PSGL-1 mAb or purified rat IgG1 (BD Biosciences)
in FACS® buffer (1% BSA and 0.1% NaN3 in PBS) for 30 min on
ice. Subsequently, eEPCs were washed twice and incubated with
PE-conjugated anti–rat Ig in FACS® buffer and 5% mouse serum
for 30 min. Analysis was performed on a Becton Dickinson FACS-
Calibur™. As a control, we used the mouse neutrophilic progen-
itor cell line 32DCl3 that stains positive for PSGL-1 with the
same antibody (29). To test for the presence of E- and P-selectin
ligands on the surface of eEPCs, we incubated 5   105–106 cells
(eEPCs or peripheral blood cells as a positive control) with 80
 g/ml E- or P-selectin human IgG chimera in FACS® buffer
supplemented with 2 mM Mg2  and 2 mM Ca2 . As a negative
control for the chimeric molecules, we used a tie2-IgG chimera
that does not bind to the cells. Specificity controls ensuring the
lectin-mediated binding of the selectin-Ig constructs was tested in
samples processed in parallel where Mg2  and Ca2  were re-
placed by 5 mM EDTA. Afterwards, we washed the cells twice
with the corresponding buffers and incubated with 10  g/ml PE-
conjugated goat-anti–human IgG for 20 min at 4 C. We washed
the cells twice, fixed them in 1% formaldehyde, and analyzed
them on the FACSCalibur™.
Statistics. Quantitative data, except the size of the subcutane-
ous tumor xenografts, are given as mean values   SD. Mean val-
ues were calculated from the average values in each animal. For
analysis of differences between the groups, one-way analysis of
variance followed by the appropriate post hoc test for individual
comparisons between the groups was performed (ANOVA). 
Results
eEPCs Retain Their Progenitor Properties after Ex Vivo Ex-
pansion. eEPCs were isolated, expanded in vitro, and flu-
orescently labeled in two different ways. In one approach,
we electroporated the cells with an EGFP construct under
the control of the phosphoglycerate kinase promoter, and
stable transfected cell lines were established that produce
EGFP (Fig. 1 A). In a second approach, we labeled cells
with DiI (Fig. 1 B). Expression analysis of the ex vivo–
expanded and –transfected cells revealed the typical expres-
sion pattern for endothelial markers as reported previously
for freshly isolated eEPCs (Fig. 1 C; reference 13). Stimula-
tion of transfected eEPCs with cAMP and retinoic acid
confirmed their ability to differentiate to more mature en-T
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1758 Embryonic EPCs and Tumor Angiogenesis
dothelial cells (Fig. 1 C). This differentiation or activation
of the eEPCs is accompanied by induction of flk-1, vWF,
sca-1, and E- and P-selectin. Interestingly, unlike mature
endothelial cells, eEPCs express angiogenic factors such as
VEGF as well as the ligands for E- and P-selectin.
Ex Vivo–Expanded eEPCs Preferentially Home to Tumor
Angiogenic Sites. Intravital microscopy of the tumor-free,
nonangiogenic dorsal skinfold chamber tissue and of the
highly angiogenic C6 glioma microvasculature demon-
strated significant differences in the hemodynamic parame-
ters (Table I). Although the control tissue was characterized
by physiologic values, the tumor microvasculature dis-
played lower blood cell velocity, wall shear rate, and wall
shear stress.
After infusion of ex vivo–expanded fluorescent eEPCs,
we observed a comparable number of circulating cells
( 100–200 per observation field) both within the tumor
(n   10 animals) and control microvasculature (n   4 ani-
mals). Of those, 43   18% and 7   6% (P   0.05) were
permanently arrested within the lumen of tumor and con-
trol blood vessels. Moreover, eEPC arrest in tumors was
remarkably heterogeneous in that the arrested cells prefer-
entially homed to certain microvascular hot spots (Fig. 1, D
and E). Importantly, all these regional differences in eEPC
arrest were not attributable to regionally distinct hemody-
namic conditions within the tumor microvasculature, indi-
cating that this preferential arrest was not simply due to low
blood flow in the hot spot areas (Table I).
eEPCs Actively Adhere to the Endothelium of Tumor Blood
Vessels. Videomicroscopy revealed two mechanisms of
permanent EPC arrest within tumor blood vessels. The
majority of cells (87   23%) actively adhered to the tumor
endothelium without affecting blood flow in this vascular
segment (Fig. 2, A–E). In contrast, the remaining cells (13  
23%) passively plugged tumor blood vessels by size re-
strictions or were trapped in dead-end vascular sprouts (Fig.
Figure 1. eEPCs home to tumor angiogenic sites. (A and B) Ex vivo–
expanded eEPCs labeled with EGFP (A) or DiI (B). (C) RNA expression
profiles by RT-PCR analysis in eEPCs before ( ) and after activation
( ) with cAMP and retinoic acid. M: 100 bp ladder molecular weight
marker. The stronger band is 800 bp. (D) Tumor microvasculature on
day 10 after implantation after contrast enhancement with rhodamine
G–conjugated dextran. (E) EGFP-eEPCs are arrested heterogeneously
within the tumor microvasculature after intraarterial injection. Same re-
gion of interest as in D.
Table I. Microhemodynamic Parameters in Control Postcapillary 
Venules and Tumor Blood Vessels
Blood vessel 
type Diameter
Mean 
velocity
Wall shear 
rate
Wall shear 
stress
 m  m/s s 1 dyne/cm3
Control 18.5   3.5 705   58 292   28 7.3   0.7
Tumor, in 
general
19.4   3.8 348   243a 159   128a 4.0   3.2a
Tumor, hot 
spots
18.0   1.8 435   338 193   149 4.8   3.7
Mean values   SD are shown; microhemodynamic parameters were
assessed in control blood vessels (n   4 animals with tumor-free skinfold
chambers), regular tumor blood vessels (n   6 animals), and in tumor
blood vessels representing hot spots of eEPC recruitment (n    5
animals). 
a*, P   0.05 versus control.
Figure 2. Circulating eEPCs
interact with the tumor endo-
thelium. (A) Tumor blood vessels
before cell injection after contrast
enhancement with FITC-conju-
gated dextran. Arrows indicate
direction of microvascular blood
flow. (B–E) Intravital micro-
scopic sequence of two DiI-
labeled eEPCs (1 and 2) interact-
ing with the vessel wall of the
identical vascular segment indi-
cated in A. Cells adhere either
permanently (1) or temporarily
(2) to the endothelium. Num-
bers depict sequential time points
in seconds (top right).T
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3, A–C). In contrast, cells within control blood vessels
were arrested predominantly by plugging the small caliber
capillaries (3–5  m; Fig. 3 C). This indicated clearly that
active, permanent adhesion of eEPCs to blood vessel endo-
thelium was a tumor-specific phenomenon.
Arrested eEPCs Extravasate and Form Multicellular Clusters
within the Tumor Interstitium. Within 1 h, the arrested
eEPCs started to extravasate from the tumor blood vessels
(Fig. 3, D and E). After 1 d, all cells were localized in the
extravascular space where they started to form multicellular
clusters (Fig. 4, A and B). Higher magnifications revealed
two types of cell morphology; 32% of the cells showed a
round morphology (Fig. 4, C and D), whereas 68% became
elongated and displayed a bipolar morphology (Fig. 4, E
and F). Interestingly, the elongated cells were localized in
the vicinity of active microvascular segments that displayed
angiogenic sprouting. This was in contrast to the control
tissue where only very few cells were localized extravascu-
larly as single cells, and of those, only 29% displayed an
elongated morphology.
eEPCs Contribute to Tumor Angiogenesis and Form Func-
tional Blood Vessels. Within a few days, the extravasated
and elongated eEPCs started to branch and form cellular net-
works. The double-labeling technique using fluorescent dex-
tran to visualize functional (i.e., perfused) tumor blood vessels
demonstrated clearly that these cells either formed microvas-
cular sprouts (Fig. 5, A–C), or progressively spanned between
individual vessels interconnecting distant microvascular seg-
ments (Fig. 5, D–F). Finally, multiple fluorescent cells lined
perfused tumor blood vessels, indicating that recruited eEPCs
had been successfully incorporated into the new tumor mi-
crovasculature (Fig. 6, A–D). Tumor cryosections stained
with fluorescent antibodies against PECAM-1 confirmed the
successful integration of injected eEPCs into the endothelial
lining of the tumor microvasculature (Fig. 6 E).
eEPCs Preferentially Incorporate into Tumor Microvascula-
ture. Quantitative analysis of eEPC homing demonstrated
that circulating eEPCs preferentially homed to the tumor
Figure 4. Morphological changes of eEPCs after extravasation on day
one after injection. (A and B) Multicellular clusters of DiI-labeled eEPCs
are located extravascularly throughout the tumor. Same regions of interest
in A and B. Squares indicate areas highlighted in (C) and (D, dotted line)
and (E) and (F, dashed line). (C–F) Higher magnification of tumor blood
vessels (C and E) and extravascular eEPCs (D and F). eEPCs either
showed a round (D) or elongated shape and displayed bipolar morphol-
ogy (F). Note the intimate relationship of cell to angiogenic vascular
sprouts (arrows). Tumor microvasculature visualized after contrast en-
hancement by FITC-dextran.
Figure 3. Mechanisms of eEPCs arrest in tumor and
control tissue. (A and B) Narrow tumor blood vessel
obliterated by plugging eEPC due to size restriction
(arrows). Same region of interest in A and B. Tumor
blood vessels and eEPCs are fluorescently marked as in
Fig. 2. (C) Sticking versus plugging as mechanisms of
eEPC arrest within tumor (left, n   10 animals) and
control (right, n   4 animals) microvasculature. Con-
trol is chamber preparation without tumor implanta-
tion. Error bars show mean   SD values. (D and E)
Demonstration of eEPC migration through the endo-
thelial lining within 1 h after intravascular arrest. Label-
ing of tumor blood vessels with rhodamine G–dextran
(D) and of eEPCs with EGFP (E). Same region of in-
terest in D and E. *, P   0.05 versus control tissue.T
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1760 Embryonic EPCs and Tumor Angiogenesis
microvasculature immediately after systemic injection (Fig.
6 F). This became even more pronounced after 60 min, due
to the continuing arrest of recirculating eEPCs. However,
not only the recruitment of eEPCs was tumor-specific but
also their extravasation, survival, and incorporation into
functional tumor blood vessels by days 1 and 4. We noted
with interest that not every arrested cell was finally incorpo-
rated. Rather, this process was characterized by  30% an-
giogenic efficiency because  55% of initially arrested cells
extravasated and survived (day 1), and 30% finally formed
functional tumor blood vessels (Fig. 6 F, day 4).
The tumor-specific incorporation of circulating eEPCs
raised the question about the proportion of the neovascula-
ture derived from the eEPCs versus that sprouting from pre-
existing vessels. To quantitate this, we counted the total
number of eEPC-positive vascular sprouts (i.e., associated
with incorporated eEPCs) and eEPC-negative vascular
sprouts, and demonstrated that eEPCs contributed to 12% of
newly forming tumor vessels. As a result, by day 4, incorpo-
rated eEPCs composed 3% of the total tumor vessel density.
To further address the specificity of angiogenic eEPC
homing, we assessed their distribution within various organs
by intravital fluorescence microscopy. After injection, we
detected individual eEPCs within the liver (37   2 mm 2),
spleen (20   4 mm 2), and lung (21   2 mm 2) represent-
ing organs that are characterized by a high organ blood flow
and fenestrated endothelium. No eEPCs were found in the
heart, pancreas, or kidney. In contrast to the angiogenic tu-
mor microvasculature, all arrested eEPCs within organs re-
tained their round morphology and were not incorporated
into the endothelial lining of blood vessels. 
Incorporation of eEPCs Does Not Enhance Tumor Vascular-
ization and Growth. Incorporation of eEPCs into the tu-
mor microvasculature may affect tumor angiogenesis, and
thereby accelerate tumor vascularization and tumor
growth. To test this possibility, we analyzed the total ves-
sel density and area of the tumors before and 4 d after
eEPC injection and compared them to tumors grown
within the skinfold chamber but lacking circulating
eEPCs. As demonstrated in Fig. 7 (A and B), incorpora-
tion of eEPCs however did not have a significant effect on
the total vessel density and tumor size. The latter was fur-
ther confirmed in subcutaneous xenografts revealing no
difference in tumor volume between animals injected with
PBS or eEPCs (Fig. 7 C).
Selectins and PSGL-1 Mediate Homing of Embryonic EPCs.
Our results indicate that homing of circulating eEPCs to
the tumor vasculature is determined by adhesive mecha-
nisms reminiscent of the interaction of leukocytes with mi-
crovascular endothelium. To gain more insight into the
underlying mechanisms, first we studied the expression of
adhesion molecules in the tumor endothelium. Immuno-
histochemistry of the C6 tumors revealed strong expression
of PECAM-1 (Fig. 8 A), moderate expression of P-selectin
(Fig. 8 B), weak expression of E-selectin (Fig. 8 C; tumor
periphery only), ICAM-1 and ICAM-2 (not depicted), and
no expression of VCAM-1, PNAd, or MAdCAM-1. Sec-
ond, we analyzed the expression of the cognate ligands by
the eEPCs. RT-PCR analysis failed to show expression of
the ligands for ICAM-1 and ICAM-2 (unpublished data),
but demonstrated a strong expression of the E- and P-selec-
tin ligands, ESL-1 and PSGL-1, respectively (Fig. 1 C). For
PSGL-1, the expression of the protein on the cell surface
could be confirmed by flow cytometry, albeit at low levels
(Fig. 8 I), as compared with the mouse neutrophilic pro-
genitor cell line 32DCl3 that was used as a positive control
(not depicted; reference 29). This indicated that eEPCs
have the ability to bind to E- and P-selectin. We tested this
notion using E- and P-selectin IgG chimera proteins. As
shown in Fig. 8 (E–H), both molecules bind to the eEPCs
in a strong and specific manner demonstrating the presence
of functional binding sites for both selectins on the cell sur-
face.
Based on these results, next we addressed the significance
of E- and P-selectin and PSGL-1 in mediating EPC hom-
ing to tumor vessels by using blocking antibodies directed
against PSGL-1 or E- and P-selectin. Pretreatment of mice
with an antibody cocktail directed simultaneously against
Figure 5. Extravasated eEPCs branch and interconnect tumor blood
vessels. (A and D) Tumor microvasculature after contrast enhancement by
FITC-dextran. (B and E) Same regions of interest as in A and D, demon-
strating DiI-labeled eEPCs. (C and F) Superimposed FITC and DiI im-
ages after adding false colors to DiI images. eEPCs are marked with green
false color. (A–C) eEPCs participate in angiogenic sprouting (arrow indi-
cates vascular sprout; day 1 after injection). (D–F) eEPCs branch and span
between individual tumor blood vessels interconnecting distant microvas-
cular segments (arrows indicate vascular sprouts; day 1 after injection). T
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E- and P-selectin, as well as pretreatment of eEPCs with an
antibody directed against PSGL-1 before injection, reduced
initial eEPC arrest on the tumor endothelium and subse-
quent eEPC incorporation into the tumor microvascula-
ture by 76 and 78%, respectively (Fig. 8 J). However, those
cells, which were arrested despite blocking PSGL-1 or E-/
P-selectin, followed the subsequent multistep process of
EPC incorporation, suggesting that selectin binding exclu-
sively mediates the initial EPC arrest.
Discussion
We have shown that eEPCs, isolated at the onset of vas-
culogenesis, can function as endothelial progenitor cells in
the adult environment and can contribute to tumor angio-
genesis after systemic injection. The recruitment of eEPCs
to tumor angiogenesis represents a multistep process, in-
cluding (a) active arrest and homing of the circulating cells
within the angiogenic microvasculature; (b) transendothe-
lial extravasation into the interstitial space; (c) extravascular
formation of cellular clusters; (d) creation of vascular
sprouts and cellular networks; and (e) incorporation into a
functional microvasculature. Finally, we have provided ev-
idence that PSGL-1 and E- and P-selectin mediate homing
of EPCs to the tumor endothelium. Thus, this paper pro-
vides the first insight into the mechanisms underlying EPC
recruitment to angiogenic sites.
Our results raise fundamental issues about the biology of
endothelial progenitor cells, taking into account the en-
tirely different milieu of eEPC origin as compared with the
transplantation site in this work. The cells originate from
E7.5 embryos and express early endothelial genes, which
match the expression profile of angioblasts located symmet-
rically at the area of the proximal lateral mesoderm, giving
rise to the primitive endocardium and major blood vessels
(13, 30). The fact that these cells can contribute to tumor
angiogenesis indicates that eEPCs, although they are pri-
marily programmed to form blood vessels during embry-
onic vascular development, retain this ability within an an-
giogenic environment in the adult.
Interestingly, cells identified recently within the side pop-
ulation of bone marrow–derived adult progenitor cells share
striking gene expression profile similarities to the eEPCs
(16). Accordingly, this adult CD34  cell subpopulation dis-
plays low flk-1 and low VE-cadherin expression, but high
tie-2 and c-kit expression, suggesting that these cells might
represent an equivalent to eEPC population in the adult.
This last possibility will further enhance the use of eEPCs as
an experimental tool to study the mechanisms underlying
EPC recruitment during neovascularization. One advantage
of this approach is that murine eEPCs supply an unlimited
cell source that is easily amenable to ex vivo expansion and
genetic manipulation. Furthermore, eEPCs represent an
ideal system for a functional analysis of molecules involved
in endothelial development and function because most of
them are expressed or can be induced in the isolated cells.
Figure 6. Functional incorporation of eEPCs into
the tumor microvasculature on day 4 after injection. (A
and B) Tumor microvasculature after contrast en-
hancement by FITC-dextran. (C and D) Same regions
of interest as in A and B, demonstrating DiI-labeled
eEPCs that line perfused tumor blood vessels, indicat-
ing successful incorporation into the new tumor mi-
crovasculature (arrows). (E) Cryosections of tumor
specimens stained with fluorescent antibodies against
PECAM-1 (red), confirming the successful integration
of EGFP-labeled eEPCs (green) into the endothelial
lining of the tumor microvasculature. (F) Quantitative
analysis of eEPCs within tumor (n   9 animals) and
control tissue (control is chamber preparation of nor-
mal tissue without tumor cell implantation; n   4 ani-
mals). Error bars show mean   SD values. *, P   0.05
versus control tissue.
Figure 7. Effects of eEPC incorporation on tumor vascularization and
tumor growth. Quantitative analysis of total vessel density (A) and tumor
area (B) of C6 xenografts implanted into the skinfold chambers of nude
mice. Measurements were performed in three to six regions of interest
per tumor and per time point, before and 4 d after injection of eEPCs
(eEPC, black bars; n   6) or PBS (control, white bars; n   5). Error bars
show mean   SD values. (C) Tumor growth curves for subcutaneous C6
xenografts implanted into the left flank regions of nude mice before and
up to 9 d after injection of eEPCs (EPC, black bars; n   4) or PBS (con-
trol, white bars; n   4). Mean values are shown.T
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1762 Embryonic EPCs and Tumor Angiogenesis
We have shown that the preferential homing of circulat-
ing eEPCs to the angiogenic tumor vasculature is deter-
mined by adhesive (i.e., active) mechanisms reminiscent of
the interaction of activated leukocytes with microvascular
endothelium (20, 31, 32). These similarities extend to the
molecular level because expression analysis in the tumor
endothelium and eEPCs, binding assays of chimeric mole-
cules in vitro, and blocking experiments using specific anti-
bodies in vivo, all demonstrate that selectins and their
ligand PSGL-1 mediate the initial adhesion of the eEPCs to
the tumor endothelium. We have also performed FACS®
analysis on eEPCs using a large panel of antibodies that rec-
ognize other known cell adhesion molecules shown previ-
ously to direct interaction of leukocytes with the vascular
wall (31, 32). The results showed that eEPCs do not ex-
press significant levels of VCAM-1, LFA-1, Mac-1,  4 1
integrin, ICAM-1, ICAM-2, and PECAM-1. Therefore,
the presence and identity of additional adhesion molecules
on eEPCs that might be involved in their interaction with
activated tumor endothelium remain currently unknown.
Adhesion of eEPCs to the tumor vessel endothelium
may be further facilitated by the tumor-specific microhe-
modynamics, which are characterized by a much lower
blood cell velocity ( 350   m/s) and wall shear stress
( 4.0 dyne/cm2) when compared with physiological con-
ditions in postcapillary venules (23; our paper). This could
explain an efficient eEPC arrest despite the relatively low
levels of PSGL-1 detected by FACS® analysis. The obser-
vation that after permanent adhesion, eEPCs extravasate
into the interstitium further indicates similar mechanisms
underlying eEPC and leukocyte recruitment and migration
through the endothelial lining. This is in contrast to a
nonangiogenic microvasculature, where eEPCs are ar-
rested by passive plugging of small caliber capillaries and
remain intravascular.
After extravasation, we revealed two patterns of eEPC
behavior. On the one hand, the cells formed small clusters,
giving rise to cellular networks that were incorporated into
the tumor microvasculature. Such network formation may
facilitate tumor vascularization by bridging distinct vascular
Figure 8. Interaction of eEPCs with tumor endo-
thelium is mediated by selectins and PSGL-1. (A–D)
Immunohistochemistry for PECAM-1 (A), P-selectin
(B), E-selectin (C), and negative control (D) confirms
P-selectin and E-selectin (the latter only in tumor pe-
riphery) expression by tumor endothelium. Tissue sec-
tions were counterstained with hematoxylin. (E–H)
E- and P-selectins bind to eEPCs. Flow cytometry us-
ing an E-selectin IgG chimera (E) or a P-selectin IgG
chimera (F) shows strong binding to eEPCs in the pres-
ence of Mg2  and Ca2  as compared with a tie2-IgG
chimera control. The binding of both proteins is
abolished in the presence of EDTA (G and H). (I)
Flow cytometry demonstrates surface expression of
the P-selectin ligand PSGL-1 in eEPCs. (J) Quantita-
tive analysis of eEPC homing to tumor endothelium
using intravital fluorescence videomicroscopy 10 min
after cell injection and after blocking of PSGL-1, or
P-selectin and E-selectin. n   3 animals per experi-
mental group. *, P   0.05.T
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beds. On the other hand, individual eEPCs were found to
localize at sprouting sites. This may reflect either a particu-
lar adhesiveness in these areas and/or a special role of EPCs
in sprout formation and guidance. These observations sug-
gest a potential role for EPCs in orchestrating the process
of angiogenesis, which would be in line with the recent
finding that hematopoietic stem cells promote vessel
sprouting in vitro and in vivo (33).
It is important to note that the experiments described in
this paper were also performed with cells after they were
differentiated to more mature endothelial cells in vitro (Fig.
1 C; reference 13), serving as a control for the progenitor
cells. Interestingly, both the homing as well as the incorpo-
ration of the differentiated cells to the tumor microvascula-
ture were lower when compared with undifferentiated
cells, indicating that the progenitor phenotype is of impor-
tance in the multistep EPC recruitment. However, due to
methodological problems, these experiments were not
conclusive in that (a) markedly less differentiated than un-
differentiated cells gained access to the control and tumor
microvasculature; and (b) the systemic injection of differen-
tiated cells often resulted in a macro- and microhemody-
namic impairment and, finally, breakdown within a few
minutes. The reason for this is not clear, but most likely it
can be attributed to the fact that differentiated cells appear
to be more “sticky” before injection, and, thus, being se-
questered within the microvasculature of large organs
(lung, liver, and spleen) and they impair microcirculation
during their first passage.
In light of the results outlined here, one can now postu-
late a plausible model for EPC recruitment and function
during tumor angiogenesis. As a first step, certain parame-
ters in the blood (e.g., high VEGF levels) mobilize and en-
hance differentiation of hematopoietic stem cells toward
the endothelial progenitor cell lineage (3, 8). At the same
time, as yet unknown mechanisms activate endothelial cells
in the vicinity of the angiogenic site so that they can bind
circulating EPCs and guide them through the vascular wall
into the interstitial tissue. There, EPCs form clusters, con-
tribute to angiogenic sprout formation, and form networks
that bridge preexisting blood vessels. Consequently, the
model outlined here suggests that this multistep process of
neovascularization via EPC recruitment is distinct from the
classic processes of vasculogenesis (in situ assembly of blood
vessels by endothelial cells differentiating from mesoderm),
angiogenesis (proliferation, sprouting, and migration of en-
dothelial cells from preexisting blood vessels), or vascular
remodeling (intussusceptive vessel growth and rearrange-
ment of vascular beds; reference 34). Therefore, we would
like to propose the term “angiomorphosis” as the process
of enhancing tissue vascularization through (a) active re-
cruitment of EPCs from the circulation by endothelial cells
and (b) the action of EPCs as organizers of the angiogenic
process (from the Greek words “angio” for blood vessel
and “morphosis” to give shape, to form). It will be interest-
ing to test in future work if bone marrow–derived EPCs
follow similar mechanisms. It is interesting to note that a
recent paper showed that functional selectin ligands and se-
lectins mediate interaction of hematopoietic CD34  stem
cells with bone marrow endothelium (35). The CD34 
stem cells are PSGL-1–positive, indicating that similar
homing mechanisms are used by bone marrow stem cells.
Our results indicate a low level of eEPC engraftment for
tumor angiogenesis,  5% of all cells passing through the
tumor microvasculature, but also shed some light on the
reason for this angiogenic inefficiency. Although  40% of
all the injected cells passing through the tumor microvascu-
lature adhered permanently to the endothelium of the tu-
mor blood vessels, most of the cells failed to extravasate
and, thus, to incorporate into new blood vessels.
Analysis of tumor growth showed that incorporation of
eEPCs did not have a significant effect on total vessel den-
sity and tumor size. The latter was further confirmed in ad-
ditional experiments using subcutaneous C6 glioma xe-
nografts that also revealed no difference in tumor growth
between animals injected with PBS or eEPCs. However, it
should be noted that the lack of an eEPC effect on tumor
growth and vascularization may be only true for a single in-
jection of cells, as performed in this work. It is also possible
that the eEPC effect is tempered because the injected cells
are competing with endogenous EPCs. In contrast, appli-
cation of eEPCs into models of tissue ischemia has resulted
in increased collateral vessel density, blood flow levels, and
tissue function (unpublished data). This led us to conclude
that eEPCs are recruited to angiogenic sites, but have a
pronounced effect on vascular density only in highly is-
chemic areas where local angiogenesis is severely impaired.
Thus, eEPCs may be used as a novel vehicle to treat tumors
without stimulating tumor growth.
As aforementioned in the previous paragraph, a single
injection of the eEPCs in this work did not exert signifi-
cant effects on tumor growth and tumor vascularization.
Therefore, we do not expect that blocking eEPC recruit-
ment via selectin inhibition in this experimental design will
significantly alter the course of tumor growth and vascular-
ization. However, it has been observed that growth rates of
primary tumors are significantly lower in P-selectin–defi-
cient mice and that this was not related to a blocking of
leukocyte infiltration (36). It is interesting to speculate that
a diminished recruitment of autologous EPCs might be re-
sponsible for this observed phenomenon.
In summary, this paper provides first insights into the
mechanisms underlying recruitment, homing, and vascular
incorporation of circulating EPCs during tumor vascular-
ization. The results are also of therapeutic interest because
they set the basis for the design of novel means to manage
blood vessel growth. A better understanding of eEPC biol-
ogy will help to exploit these cells for somatic cell–based
therapeutic approaches.
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